Key Highlights

  • MYQORZO generated USD 44.5 million of net product Revenue in the third quarter, including USD 43.1 million from the United States and USD 1.4 million from Europe, after no product sales a year earlier.
  • Total revenues reached USD 47.6 million compared with USD 1.9 million, while the net loss contracted to USD 190.1 million, or USD 1.37 per share, from USD 306.2 million, or USD 2.55.
  • Selling, general and administrative expense increased USD 43.7 million to USD 113.1 million as the commercial launch ramped up, pushing total operating expenses to USD 214.6 million.
  • Cash, cash equivalents and investments stood at USD 1.6 billion on September 30, 2026, and a PDUFA date of November 14, 2026 covers a supplemental application for MYQORZO.

MYQORZO Sales Reshape the Revenue Mix

Cytokinetics (NASDAQ:CYTK) lodged its Quarterly Report on November 4, 2026, covering the three months ended September 30, 2026. The biopharmaceutical company centers on muscle activators and inhibitors, and its first commercial product, MYQORZO (aficamten), gained FDA approval in December 2025 for symptomatic obstructive hypertrophic cardiomyopathy. Net product revenue was USD 44.5 million, nine-month product revenue reached USD 74.6 million, and collaboration revenue came to USD 3.1 million. Total revenue of USD 47.6 million compares with USD 1.9 million a year earlier. Nine-month total revenue stood at USD 95.5 million against USD 70.3 million, since the prior-year period included a larger Bayer license and milestone payment.

Why the Loss Narrowed and Why It Remains Large

The USD 190.1 million net loss sits below USD 306.2 million, but the prior-year quarter carried a USD 121.2 million Debt conversion expense, so part of the improvement is a timing effect. Operating costs moved higher regardless: selling, general and administrative expense hit USD 113.1 million from USD 69.5 million on external launch spending and staffing, while Research and Development totaled USD 99.3 million, up USD 2.0 million. Nine-month net loss was USD 594.9 million, or USD 4.52 per share, compared with USD 601.9 million, or USD 5.04. Operating cash outflow reached USD 429.3 million over nine months, and management expects selling expenses to climb meaningfully during 2026.

PDUFA Timing, Label Expansion and a USD 1.6 Billion Cash Cushion

Cytokinetics (NASDAQ:CYTK) held USD 1.6 billion of cash, cash equivalents and investments, which it judges sufficient for at least 12 months. A supplemental application adding MAPLE-HCM data to the label has a PDUFA date of November 14, 2026. Positive ACACIA-HCM findings in non-obstructive disease were reported in August 2026, and a filing is planned for the fourth quarter. MYQORZO also won UK authorization in July 2026 and Canadian authorization in October 2026, while European commercial activity is set to begin in Germany. Launch pace, the safety program the drug requires, sizable operating losses and regulatory decisions that could differ from expectations are the main risks.

Where Things Stand

The sales narrowed the loss only partly. Cytokinetics (NASDAQ:CYTK) converted USD 44.5 million of MYQORZO product revenue into a USD 190.1 million loss, down from USD 306.2 million, but that earlier quarter included a USD 121.2 million debt conversion expense and launch spending is still climbing. The Balance Sheet holds USD 1.6 billion. Next are the FDA decision date of November 14, 2026, the European launch that begins in Germany and whether product revenue outpaces selling costs.